Why Protagonist Therapeutics Stock Is Back in Focus

Protagonist Therapeutics (PTGX) is in the spotlight after FDA approval of ICOTYDE for moderate to severe plaque psoriasis, a Priority Review for rusfertide, and a Takeda opt out that triggers substantial payments.

Despite the recent pullback, with a 1-month share price return of 4.4% and a 7-day share price return of 2%, Protagonist Therapeutics still has a 90-day share price return of 19.1%. The 1-year total shareholder return of 136.16% and 3-year total shareholder return of 292.91% point to strong momentum built around ICOTYDE's approval and progress on rusfertide.

If you are looking beyond a single biotech story, this is a good moment to scan for other high potential opportunities via the 35 healthcare AI stocks.

With ICOTYDE on the market, rusfertide under Priority Review, a market cap of about US$6.4b and an implied discount to some valuation estimates, the key question is simple: is there still upside here, or is the market already pricing in future growth?

What The Current Valuation Is Really Saying

On Simply Wall St's DCF model, Protagonist Therapeutics has an estimated future cash flow value of $373.32 per share, compared with the last close of $99.21. That gap implies the stock is trading at a steep discount to the model's fair value anchor.

The DCF approach projects future cash flows and then discounts them back to today, using a rate that reflects risk and the time value of money. It relies heavily on assumptions about future revenue, margins, and reinvestment, which can materially shift the output if those inputs change.

For a biotech that is currently loss making, with reported revenue of $46.02m and a net loss of $130.15m, a cash flow focused model attempts to look past current losses and capture potential future cash generation from ICOTYDE, rusfertide, and the rest of the pipeline.

That context helps explain why a company with a negative return on equity of 21.17% and a P/B ratio of 10.3x against a US Biotechs industry average of 2.3x can still screen as trading 73.4% below an internal fair value estimate. The market price reflects what investors are currently willing to pay, while the DCF output reflects one view of what future cash flows might justify over time.

Result: DCF Fair value of $373.32 (UNDERVALUED)

However, the story can change quickly if clinical timelines slip or if ICOTYDE and rusfertide uptake falls short of what investors currently expect.

What Analyst Targets Suggest Instead

Analysts are not as optimistic as the SWS DCF model. Their average price target of $113.33 is only about 14% above the last close of $99.21, which points to a much tighter margin for error than a DCF value of $373.32 per share.

That gap leaves you weighing two very different stories: one where long term cash flows justify a far higher price, and another where most of the upside may already be reflected. Which do you think is closer to reality?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Protagonist Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 51 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With such mixed signals on value, sentiment is clearly split, so do not wait too long to check the data yourself and decide what makes sense for your goals. To see what investors are currently optimistic about, start with the 2 key rewards

Looking for more investment ideas?

If you only stop at one stock, you risk missing other opportunities that fit your style and risk comfort, so broaden your search before making your next move.

• Target value opportunities early by scanning companies that look mispriced on quality and fundamentals with the 51 high quality undervalued stocks.
• Strengthen your core holdings by focusing on companies with robust finances through the solid balance sheet and fundamentals stocks screener (46 results).
• Get ahead of the crowd by reviewing a screener containing 25 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.